Laromestrocel

拉罗迈托赛

Report date: 2025/11/11 17:42:27

Base Information

Drug NameLaromestrocel
Drug Alias NameAllogeneic Human Mesenchymal Stem Cells (Longeveron)Longeveron human mesenchymal stem cells (Longeveron)LMSC (Longeveron)Lomecel-B
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)FrailtyMetabolic Diseases +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLongeveron Inc
China Registration ClassN/A

Develop Information

Active CompaniesLongeveron Inc
Inactive CompaniesNational Heart, Lung, And Blood Institute (Nhlbi)
Active IndicationsCoronavirus Disease 2019 (COVID-19)FrailtyCardiomyopathy, Dilated +[6] 
Inactive IndicationsMetabolic DiseasesVascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A